Cantor Fitzgerald reissued their overweight rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $155.00 price target on the biopharmaceutical company’s stock.
A number of other analysts have also recently issued reports on GILD. Rothschild & Co Redburn reduced their price objective on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Royal Bank Of Canada cut their price target on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 7th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Wednesday, May 20th. Needham & Company LLC reissued a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research note on Wednesday. Finally, Morgan Stanley dropped their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a report on Monday, July 27th. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $158.04.
Get Our Latest Stock Analysis on GILD
Gilead Sciences Price Performance
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the previous year, the firm posted $2.01 earnings per share. The firm’s revenue was up 10.6% on a year-over-year basis. Equities research analysts expect that Gilead Sciences will post -0.49 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.
Insider Buying and Selling
In other news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares of the company’s stock, valued at $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares of the company’s stock, valued at $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 82,000 shares of company stock worth $10,641,790. 0.30% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Paulson Wealth Management Inc. grew its holdings in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 67 shares in the last quarter. Essex Financial Services Inc. raised its stake in shares of Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after purchasing an additional 71 shares during the period. Davidson Trust Co. boosted its holdings in shares of Gilead Sciences by 4.1% in the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 74 shares during the last quarter. Alpha Cubed Investments LLC grew its position in Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after buying an additional 75 shares during the period. Finally, Personal CFO Solutions LLC increased its holdings in Gilead Sciences by 1.7% during the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.
More Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead raised its 2026 base-business outlook, citing continued strength in its HIV portfolio and growing PrEP demand. Management also highlighted Trodelvy growth and two potential product launches in the second half of the year. GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
- Positive Sentiment: Second-quarter revenue of $7.80 billion exceeded expectations, and revenue increased 10.6% year over year. Although reported earnings were distorted by acquisition-related items, the underlying operating performance was viewed as stronger than the headline loss suggests. Gilead lifts sales outlook on strong Q2 HIV growth despite acquisition-related loss
- Positive Sentiment: Analysts at Cantor Fitzgerald and Needham & Company reiterated favorable views, assigning Gilead Overweight and Buy ratings, respectively. Gilead Sciences Earns Overweight Rating from Cantor Fitzgerald Gilead Sciences Earns Buy Rating from Needham
- Neutral Sentiment: Gilead’s research pipeline could provide longer-term growth, but investors are weighing whether development spending and potential launches can translate into sustainable commercial returns. Can Gilead Sciences Turn Research Into Growth?
- Neutral Sentiment: RBC raised its Gilead price target to $123, signaling a more constructive view, though the target remains below the reference market price and therefore offers limited near-term upside. RBC Increases Gilead Sciences Price Target
- Negative Sentiment: MSD and Gilead discontinued a Phase III Trodelvy-Keytruda study after lackluster interim data, weakening expectations for a major combination-therapy expansion of Trodelvy. MSD and Gilead scrap Phase III Trodelvy-Keytruda study
Gilead Sciences Company Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
